1. DiGiovanna MP: Clinical significance of HER-2/neu overexpression: Part I. Principles and Practice of Oncology. Edited by: DeVita VT Jr, Hellman S, Rosenberg SA. 1999, Cedar Knolls: Lippincott Williams & Wilkins, [Rosenberg SA (Series Editor): Principles and Practice of Oncology Updates, vol. 13]., 9
2. DiGiovanna MP: Clinical significance of HER-2/neu overexpression: Part II. Principles and Practice of Oncology. Edited by: DeVita VT Jr, Hellman S, Rosenberg SA. 1999, Cedar Knolls: Lippincott Williams & Wilkins, [Rosenberg SA (Series Editor): Principles and Practice of Oncology Updates, vol. 13]., 10
3. Carter P, Presta L, Gorman CM, Ridgway JBB, Henner D, Wong WLT, Rowland AM, Kotts C, Carver ME, Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992, 89: 4285-4289. 10.1073/pnas.89.10.4285.
4. Chazin VR, Kaleko M, Miller AD, Slamon DJ: Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene. 1992, 7: 1859-1866.
5. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A: p185 HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989, 9: 1165-1172.